Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

75.37USD
19 Jul 2019
Change (% chg)

$-0.52 (-0.69%)
Prev Close
$75.89
Open
$75.95
Day's High
$75.95
Day's Low
$74.78
Volume
477,645
Avg. Vol
317,033
52-wk High
$124.15
52-wk Low
$60.28

Select another date:

Mon, Apr 8 2019

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up

April 8 Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Alnylam, Regeneron to partner for RNAi treatments

April 8 Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Side effects of Alnylam's gene-silencing drug raise concerns, shares slip

Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease.

UPDATE 2-Side effects of Alnylam's gene-silencing drug raise concerns, shares slip

March 6 Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease.

Alnylam's gene-silencing drug meets main goal in late-stage study

March 6 Alnylam Pharmaceuticals Inc said on Wednesday its gene-silencing drug for treating a rare, painful disease met the main goal in a late-stage trial.

Select another date: